An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Although lifestyle choices can lead to heart disease, there are certain diagnoses that are the product of genetics alone.

BACKGROUND: Shared genetic and lifestyle risk factors may underlie the development of both coronary artery disease (CAD) and ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Shared decision-making forms an increasingly important part of the expert consultation for athletes with genetic heart ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

This segment is sponsored by Family Heart Foundation.Heart disease remains the leading cause of death in America, but few ...

Inherited or genetic heart disorders ... Elevated Lp(a) is linked to a higher risk of heart disease, stroke, and other cardiovascular issues, particularly among individuals of African ancestry.

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the United ...